Mohammad Reza Haghshenas - Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Many physiological and pathological processes in cancers are controlled by protein complexes and protein-protein interactions. Proteomics technologies investigate and identify the expression and function of proteins in large scale. Clinical proteomics refers to the utility of data obtained from proteomics in clinic. A detail characterization about molecular mechanisms underlying the development of diseases, particularly in cancer, may be essential in terms of diagnosis and treatment. In this context, proteomics creates the bridge between molecular diagnostics and therapeutics, and their integration will be imperative to improve monitoring of patients for development of personalized medicine. Some identified proteins via the proteomics studies have been recently implemented in clinical trials for evaluation of response to drugs, some identified proteins are under development in clinic laboratories and some others are commercially available in clinic to personalized cancer management.